A Randomized, Comparative, Prospective Study of Daily Trimethoprim / Sulfamethoxazole (TMS) and Thrice-Weekly TMS for Prophylaxis Against PCP in HIV-Infected Patients
Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
Previous tests have shown that SMX/TMP given daily is effective in preventing recurrence of PCP and may be effective in preventing PCP in patients who have never developed it. Because SMX/TMP can cause side effects, this study will attempt to determine the safest and most effective dose of this combination.
Patients receive SMX/TMP orally on a daily or thrice-weekly basis. Patients are clinically evaluated every 4 months. Patients on daily SMX/TMP who develop a drug-related toxicity may be switched to thrice-weekly SMX/TMP. Duration of follow-up is 12 months.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- Patients must have:
- • HIV infection.
- • CD4 count \<= 200 cells/mm3 OR a history of prior PCP.
- • No active pneumocystosis. Patients or their guardians must sign informed consent. Pregnant patients are eligible at the clinician's discretion. Patients who do not meet required laboratory values may be eligible at the discretion of the clinician.
- • Exclusion Criteria
- Co-existing Condition:
- Patients with the following symptoms and conditions are excluded:
- • Known treatment-limiting reaction to sulfonamides or trimethoprim.
- Concurrent Medication:
- Excluded:
- • Other PCP prophylaxis or medication with anti-PCP activity.
About National Institute Of Allergy And Infectious Diseases (Niaid)
The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Denver, Colorado, United States
Wilmington, Delaware, United States
Washington, District Of Columbia, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
New Orleans, Louisiana, United States
Detroit, Michigan, United States
Detroit, Michigan, United States
Camden, New Jersey, United States
Newark, New Jersey, United States
Bronx, New York, United States
Brooklyn, New York, United States
New York, New York, United States
New York, New York, United States
Philadelphia, Pennsylvania, United States
Richmond, Virginia, United States
Stanford, California, United States
San Francisco, California, United States
Portland, Oregon, United States
Baltimore, Maryland, United States
Baltimore, Maryland, United States
Albuquerque, New Mexico, United States
Albuquerque, New Mexico, United States
Seattle, Washington, United States
Patients applied
Trial Officials
W El-Sadr
Study Chair
R Luskin-Hawk
Study Chair
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials